TY - JOUR
T1 - Plasma YKL-40 is elevated in patients with recurrent atrial fibrillation after catheter ablation
AU - Henningsen, Kristoffer Mads
AU - Nilsson, Brian
AU - Johansen, Julia S
AU - Chen, Xu
AU - Pehrson, Steen
AU - Svendsen, Jesper Hastrup
AU - Henningsen, K.M.
AU - Nilsson, B.
AU - Johansen, J.S.
AU - Chen, X.
AU - Pehrson, S.
AU - Svendsen, J.H.
N1 - Keywords: Adult; Aged; Aged, 80 and over; Atrial Fibrillation; Biological Markers; Catheter Ablation; Electrocardiography; Electrocardiography, Ambulatory; Enzyme-Linked Immunosorbent Assay; Female; Follow-Up Studies; Glycoproteins; Humans; Lectins; Logistic Models; Male; Middle Aged; Recurrence; Treatment Outcome
PY - 2010/6
Y1 - 2010/6
N2 - Aim: To study plasma YKL-40 in patients with atrial fibrillation (AF) treated with radiofrequency (RF) catheter ablation and to assess the predictive role of plasma YKL-40 and its changes after restoration of sinus rhythm (SR). Methods: Forty-six patients (mean age 55 years, range 31-81) with paroxysmal/persistent AF were treated with RF catheter ablation; Holter monitoring for 14 days was performed before ablation and after 3 months. Recurrent symptomatic AF or atrial tachycardia >10 min was considered failure, and the patients were offered a second ablation session. YKL-40 was determined in plasma samples taken prior to ablation and at follow-up visits up to 12 months after ablation. Results: After a maximum of two ablations, 19 patients (41%) had SR without recurrence of AF after 12 months. The patients with no recurrence of AF had significantly lower baseline plasma levels of YKL-40 prior to ablation compared to patients with recurrence of AF (31 vs. 62 μg/l, P = 0.029). Plasma YKL-40 was not an independent predictor of recurrence of AF after ablation. No significant changes in plasma YKL-40 levels were seen from baseline to follow-up at 12 months. Conclusion: In patients with paroxysmal or persistent AF treated with catheter ablation, high plasma YKL-40 before ablation is associated with recurrence of AF.
AB - Aim: To study plasma YKL-40 in patients with atrial fibrillation (AF) treated with radiofrequency (RF) catheter ablation and to assess the predictive role of plasma YKL-40 and its changes after restoration of sinus rhythm (SR). Methods: Forty-six patients (mean age 55 years, range 31-81) with paroxysmal/persistent AF were treated with RF catheter ablation; Holter monitoring for 14 days was performed before ablation and after 3 months. Recurrent symptomatic AF or atrial tachycardia >10 min was considered failure, and the patients were offered a second ablation session. YKL-40 was determined in plasma samples taken prior to ablation and at follow-up visits up to 12 months after ablation. Results: After a maximum of two ablations, 19 patients (41%) had SR without recurrence of AF after 12 months. The patients with no recurrence of AF had significantly lower baseline plasma levels of YKL-40 prior to ablation compared to patients with recurrence of AF (31 vs. 62 μg/l, P = 0.029). Plasma YKL-40 was not an independent predictor of recurrence of AF after ablation. No significant changes in plasma YKL-40 levels were seen from baseline to follow-up at 12 months. Conclusion: In patients with paroxysmal or persistent AF treated with catheter ablation, high plasma YKL-40 before ablation is associated with recurrence of AF.
U2 - 10.1007/s00011-009-0146-z
DO - 10.1007/s00011-009-0146-z
M3 - Journal article
C2 - 20012147
SN - 1023-3830
VL - 59
SP - 463
EP - 469
JO - Inflammation Research
JF - Inflammation Research
IS - 6
ER -